Evidence map›Paper›PMID 29573551›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2018

Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation.

S Sandy An, C Patrick Henson, Robert E Freundlich, Matthew D McEvoy

Registry-linked trialOpen access · hybridAbstract readCase Reports
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03783091 (A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03783091 phase2completednot on this mapstarted 2019, after this paper: background citation

A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock

TypeinterventionalSponsorMedical College of WisconsinRan2019 to 2023Enrolled20ConditionsSeptic ShockArmsHydroxocobalamin, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. High-dose hydroxocobalamin in end-stage liver disease and liver transplantation.Drugs & therapy perspectives : for rational drug selection and use · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S Sandy AnDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
C Patrick HensonDivision of Critical Care, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Robert E FreundlichDivision of Critical Care, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Matthew D McEvoyDepartment of Anesthesiology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · US

Funding

Institutional Career Development CoreKL2TR002245 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2017 to 2026
$9.3M
NCATS NIH HHS KL2 TR002245
6 · The paper itself

Abstract

A 66-year-old man with cryptogenic cirrhosis secondary to nonalcoholic steatohepatitis presented for orthotopic liver transplantation. Following organ reperfusion, the patient developed vasoplegic syndrome, with arterial blood pressures of approximately 60-70/30-40 mm Hg (mean arterial pressure [MAP] <45 mm Hg) for >90 minutes. He required high-dose norepinephrine and vasopressin infusions, as well as i.v. bolus doses of norepinephrine and vasopressin to reach a goal MAP> 60 mm Hg. There was minimal response to a 2 mg/kg i.v. bolus of methylene blue. Following the administration of 5 g of i.v.hydroxocobalamin, the patient had a profound improvement in arterial blood pressure, with subsequent discontinuation of the vasopressin infusion and rapid reduction of norepinephrine infusion from 20 to 2 μg/min. While there have been several reports of the efficacy of hydroxocobalamin for vasoplegia after cardiopulmonary bypass, there have been only limited cases of hydroxocobalamin used in liver transplantation, and none with high-dose administration. We present a case of vasoplegic syndrome during liver transplantation that was refractory to high-dose vasopressors and methylene blue but responsive to high-dose i.v. hydroxocobalamin.

Indexed as

Liver TransplantationAgedHumansHydroxocobalaminMaleVasoplegiaHydroxocobalaminanesthesia/pain managementclinical research/practiceliver diseaseliver transplantation: auxiliaryoff-label drug usephysician education

Identifiers

PMID29573551
PMCPMC6138872
OpenAlexW2791107046

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.